Author:
Erkkilä Mikael T.,Reichert David,Gesperger Johanna,Kiesel Barbara,Roetzer Thomas,Mercea Petra A.,Drexler Wolfgang,Unterhuber Angelika,Leitgeb Rainer A.,Woehrer Adelheid,Rueck Angelika,Andreana Marco,Widhalm Georg
Abstract
AbstractMaximal safe tumor resection remains the key prognostic factor for improved prognosis in brain tumor patients. Despite 5-aminolevulinic acid-based fluorescence guidance the neurosurgeon is, however, not able to visualize most low-grade gliomas (LGG) and infiltration zone of high-grade gliomas (HGG). To overcome the need for a more sensitive visualization, we investigated the potential of macroscopic, wide-field fluorescence lifetime imaging of nicotinamide adenine dinucleotide (NADH) and protoporphyrin IX (PPIX) in selected human brain tumors. For future intraoperative use, the imaging system offered a square field of view of 11 mm at 250 mm free working distance. We performed imaging of tumor tissue ex vivo, including LGG and HGG as well as brain metastases obtained from 21 patients undergoing fluorescence-guided surgery. Half of all samples showed visible fluorescence during surgery, which was associated with significant increase in PPIX fluorescence lifetime. While the PPIX lifetime was significantly different between specific tumor tissue types, the NADH lifetimes did not differ significantly among them. However, mainly necrotic areas exhibited significantly lower NADH lifetimes compared to compact tumor in HGG. Our pilot study indicates that combined fluorescence lifetime imaging of NADH/PPIX represents a sensitive tool to visualize brain tumor tissue not detectable with conventional 5-ALA fluorescence.
Funder
Horizon 2020 Framework Programme
Austrian National Foundation for Research, Technology and Development
European Research Council
Austrian Science Fund
Österreichischen Akademie der Wissenschaften
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Ray, S., Bonafede, M. M. & Mohile, N. A. Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am. Health Drug Benefits 7, 140–149 (2014).
2. Norden, A. D. et al. A real-world claims analysis of costs and patterns of care in treated patients with glioblastoma multiforme in the united states. J. Manag. Care Spec. Pharm. 25, 428–436 (2019).
3. Sanai, N., Polley, M.-Y., McDermott, M. W., Parsa, A. T. & Berger, M. S. An extent of resection threshold for newly diagnosed glioblastomas: Clinical article. J. Neurosurg. 115, 3–8 (2011).
4. DSouza, A. V., Lin, H., Henderson, E. R., Samkoe, K. S. & Pogue, B. W, ,. Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging. J. Biomed. Opt. 21, 080901 (2016).
5. Valdés, P. A., Roberts, D. W., Lu, F.-K. & Golby, A. Optical technologies for intraoperative neurosurgical guidance. Neurosurg. Focus 40, 8 (2016).
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献